IL256111B2 - Treatment of pac combinations - Google Patents
Treatment of pac combinationsInfo
- Publication number
- IL256111B2 IL256111B2 IL256111A IL25611117A IL256111B2 IL 256111 B2 IL256111 B2 IL 256111B2 IL 256111 A IL256111 A IL 256111A IL 25611117 A IL25611117 A IL 25611117A IL 256111 B2 IL256111 B2 IL 256111B2
- Authority
- IL
- Israel
- Prior art keywords
- pac
- cancer
- combination
- vemurafenib
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171882P | 2015-06-05 | 2015-06-05 | |
| US201662345629P | 2016-06-03 | 2016-06-03 | |
| PCT/US2016/036063 WO2016197129A1 (en) | 2015-06-05 | 2016-06-06 | Pac-1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL256111A IL256111A (en) | 2018-02-28 |
| IL256111B1 IL256111B1 (en) | 2023-05-01 |
| IL256111B2 true IL256111B2 (en) | 2023-09-01 |
Family
ID=57442182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256111A IL256111B2 (en) | 2015-06-05 | 2016-06-06 | Treatment of pac combinations |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10350207B2 (enExample) |
| EP (1) | EP3302478B1 (enExample) |
| JP (1) | JP7033451B2 (enExample) |
| KR (1) | KR102656027B1 (enExample) |
| CN (2) | CN117257802A (enExample) |
| AU (1) | AU2016271527B2 (enExample) |
| BR (1) | BR112017026140A2 (enExample) |
| CA (1) | CA2987340C (enExample) |
| DK (1) | DK3302478T3 (enExample) |
| ES (1) | ES2906763T3 (enExample) |
| IL (1) | IL256111B2 (enExample) |
| MX (1) | MX380835B (enExample) |
| RU (1) | RU2720509C2 (enExample) |
| WO (1) | WO2016197129A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104507479B (zh) * | 2012-03-06 | 2017-08-18 | 伊利诺伊大学评议会 | 通过联合治疗的半胱天冬酶‑3酶原激活 |
| AU2016271527B2 (en) * | 2015-06-05 | 2021-09-02 | The Board Of Trustees Of The University Of Illinois | PAC-1 combination therapy |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP7349155B2 (ja) * | 2017-11-17 | 2023-09-22 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | 二元的なｍｅｋシグナル伝達の低減によるがん治療 |
| WO2020072774A1 (en) * | 2018-10-05 | 2020-04-09 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| EP3976062A4 (en) * | 2019-05-30 | 2023-06-14 | The Board Of Trustees Of The University Of Illinois | PROCASPASE-3 ACTIVATION AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER |
| WO2022006512A1 (en) * | 2020-07-02 | 2022-01-06 | The Board Of Regents Of The University Of Texas System | Methods of treatment for melanoma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138279A1 (en) * | 2013-03-05 | 2014-09-12 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US20150017264A1 (en) * | 2012-03-06 | 2015-01-15 | Vanquish Oncology, Inc. | Procaspase 3 activation by combination therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| FR2757866B1 (fr) | 1996-12-30 | 2004-12-17 | Catalyse | Polymeres comportant des groupes ammoniums quaternaires, leur utilisation pour la fabrication d'un materiau a propretes antibacteriennes et leurs procedes de preparation |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20070049602A1 (en) | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| CA2751987C (en) | 2009-02-09 | 2017-11-28 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| US8574289B2 (en) * | 2009-02-09 | 2013-11-05 | St. Jude Medical, Cardiology Division, Inc. | Inflatable minimally invasive system for delivering and securing an annular implant |
| US20140348819A1 (en) * | 2011-06-24 | 2014-11-27 | Dana-Farber Cancer Institute, Inc. | Methods of Treating Cancer |
| US8916705B2 (en) | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
| AU2013225682B2 (en) | 2012-03-02 | 2016-04-14 | The Board Of Trustees Of The University Of Illinois | Potent anticancer activity via dual compound activation |
| US20130228486A1 (en) * | 2012-03-05 | 2013-09-05 | Ronald Mark Buck | Top mounting bottle container |
| CN104540501B (zh) * | 2012-03-06 | 2016-11-23 | 伊利诺伊大学评议会 | 用于胶质母细胞瘤的半胱天冬酶酶原结合的疗法 |
| US20150141470A1 (en) * | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| BR112015002357B1 (pt) | 2012-08-03 | 2022-03-15 | The Board Of Trustees Of The University Of Illinois | Compostos e composições ativadores de enzimas |
| EP2917348A1 (en) * | 2012-11-06 | 2015-09-16 | InteRNA Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| EP3003316B1 (en) * | 2013-05-31 | 2020-07-22 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US11007174B2 (en) * | 2013-07-12 | 2021-05-18 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of melanoma |
| AU2016271527B2 (en) * | 2015-06-05 | 2021-09-02 | The Board Of Trustees Of The University Of Illinois | PAC-1 combination therapy |
-
2016
- 2016-06-06 AU AU2016271527A patent/AU2016271527B2/en active Active
- 2016-06-06 CN CN202311252422.3A patent/CN117257802A/zh active Pending
- 2016-06-06 CA CA2987340A patent/CA2987340C/en active Active
- 2016-06-06 BR BR112017026140-5A patent/BR112017026140A2/pt not_active Application Discontinuation
- 2016-06-06 EP EP16804655.5A patent/EP3302478B1/en active Active
- 2016-06-06 US US15/579,689 patent/US10350207B2/en active Active
- 2016-06-06 MX MX2017015532A patent/MX380835B/es unknown
- 2016-06-06 CN CN201680045123.4A patent/CN108135896A/zh active Pending
- 2016-06-06 IL IL256111A patent/IL256111B2/en unknown
- 2016-06-06 KR KR1020187000157A patent/KR102656027B1/ko active Active
- 2016-06-06 ES ES16804655T patent/ES2906763T3/es active Active
- 2016-06-06 JP JP2017562987A patent/JP7033451B2/ja active Active
- 2016-06-06 WO PCT/US2016/036063 patent/WO2016197129A1/en not_active Ceased
- 2016-06-06 DK DK16804655.5T patent/DK3302478T3/da active
- 2016-06-06 RU RU2017146346A patent/RU2720509C2/ru active
-
2019
- 2019-06-10 US US16/436,542 patent/US11129830B2/en active Active
-
2021
- 2021-09-28 US US17/487,473 patent/US12336992B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017264A1 (en) * | 2012-03-06 | 2015-01-15 | Vanquish Oncology, Inc. | Procaspase 3 activation by combination therapy |
| WO2014138279A1 (en) * | 2013-03-05 | 2014-09-12 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2906763T3 (es) | 2022-04-20 |
| JP7033451B2 (ja) | 2022-03-10 |
| EP3302478B1 (en) | 2021-11-17 |
| RU2720509C2 (ru) | 2020-04-30 |
| US20190358229A1 (en) | 2019-11-28 |
| US20180161326A1 (en) | 2018-06-14 |
| BR112017026140A2 (pt) | 2018-08-14 |
| RU2017146346A (ru) | 2019-07-09 |
| KR102656027B1 (ko) | 2024-04-08 |
| AU2016271527B2 (en) | 2021-09-02 |
| EP3302478A4 (en) | 2019-02-27 |
| US20220088019A1 (en) | 2022-03-24 |
| CA2987340A1 (en) | 2016-12-08 |
| US11129830B2 (en) | 2021-09-28 |
| IL256111B1 (en) | 2023-05-01 |
| US10350207B2 (en) | 2019-07-16 |
| MX2017015532A (es) | 2018-04-30 |
| RU2017146346A3 (enExample) | 2019-11-11 |
| IL256111A (en) | 2018-02-28 |
| US12336992B2 (en) | 2025-06-24 |
| AU2016271527A1 (en) | 2017-12-14 |
| CA2987340C (en) | 2024-04-02 |
| DK3302478T3 (da) | 2022-02-14 |
| CN108135896A (zh) | 2018-06-08 |
| CN117257802A (zh) | 2023-12-22 |
| JP2018516936A (ja) | 2018-06-28 |
| MX380835B (es) | 2025-03-12 |
| WO2016197129A1 (en) | 2016-12-08 |
| EP3302478A1 (en) | 2018-04-11 |
| KR20180083842A (ko) | 2018-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12336992B2 (en) | PAC-1 combination therapy | |
| AU2016213862B2 (en) | Procaspase 3 activation by combination therapy | |
| IL311471A (en) | Combination therapy | |
| AU2013230985B2 (en) | Procaspase combination therapy for glioblastoma | |
| US12168006B2 (en) | Cancer therapy by degrading dual MEK signaling | |
| WO2024220427A1 (en) | Treatment of cancer with a mek kinase inhibitor | |
| HK1253828B (en) | Pac-1 combination therapy | |
| AU2017330814B2 (en) | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor | |
| TW202539622A (zh) | 包含n,n-二甲基亞雙胍的製劑、和包含n,n-二甲基亞雙胍與藥物的藥物組合、組合物、試劑盒及其用途和製備方法 | |
| AU2013230994B2 (en) | Procaspase 3 activation by combination therapy |